levofloxacin has been researched along with Tularemia in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 3 (23.08) | 29.6817 |
| 2010's | 9 (69.23) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Petersen, JM; Urich, SK | 1 |
| Dean, RE; Lever, MS; Nelson, M; Pearce, PC; Simpson, AJ; Stevens, DJ | 1 |
| Albrecht, MT; Dreier, TM; Houchens, CR; Larsen, JC; Smith, AP; Stundick, MV | 1 |
| Kaufmann, M; Knabbe, C; Seibold, E; Splettstoesser, W; Weile, J | 1 |
| Boone, I; Hassler, D; Nguyen, T; Pfaff, G; Splettstoesser, WD; Wagner-Wiening, C | 1 |
| Erdem, M; Kostakoglu, U; Tanriverdi Çayci, Y; Uzun, MÖ; Yanik, K; Yilmaz, G | 1 |
| Gutting, BW; Kanev, IL; Morozov, VN; Nwabueze, AO; Pepin, RE; Propst, CN; van Hoek, ML | 1 |
| Atkins, HS; Flick-Smith, HC; Hall, CA; Harding, SV; Titball, RW | 1 |
| Carness, P; Chopra, AK; Eaves-Pyles, T; Haithcoat, JL; Kirtley, M; Klimpel, GR; Moen, ST; Nasr, AB; Niesel, DW; Peterson, JW; Taormina, J | 1 |
| Eaves-Pyles, TD; Jezek, GE; Pyles, RB | 1 |
| Bens, G; Berton, M; Estève, E; Nojavan, H | 1 |
| Hooper, CJ; Limaye, AP | 1 |
| Aranda, EA | 1 |
2 review(s) available for levofloxacin and Tularemia
| Article | Year |
|---|---|
Animal models for Francisella tularensis and Burkholderia species: scientific and regulatory gaps toward approval of antibiotics under the FDA Animal Rule.
Topics: Animals; Anti-Bacterial Agents; Burkholderia; Burkholderia Infections; Ciprofloxacin; Disease Models, Animal; Drug Approval; Francisella tularensis; Government Regulation; Levofloxacin; Tularemia; United States; United States Food and Drug Administration | 2013 |
Treatment of tularemia with fluoroquinolones: two cases and review.
Topics: Adult; Anti-Infective Agents; Bacteremia; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Tularemia | 1999 |
11 other study(ies) available for levofloxacin and Tularemia
| Article | Year |
|---|---|
In vitro susceptibility of isolates of Francisella tularensis types A and B from North America.
Topics: Anti-Bacterial Agents; Francisella tularensis; Humans; Microbial Sensitivity Tests; North America; Tularemia | 2008 |
Bioavailability and efficacy of levofloxacin against Francisella tularensis in the common marmoset (Callithrix jacchus).
Topics: Animals; Anti-Bacterial Agents; Callithrix; Chromatography, Liquid; Drug Administration Schedule; Female; Francisella tularensis; Levofloxacin; Male; Ofloxacin; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Treatment Outcome; Tularemia | 2010 |
Treatment of tularemia in patient with chronic graft-versus-host disease.
Topics: Anti-Bacterial Agents; Chronic Disease; Doxycycline; Francisella tularensis; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Pneumonia; Tularemia | 2013 |
Tularaemia in southwest Germany: Three cases of tick-borne transmission.
Topics: Adult; Aged; Animals; Anti-Bacterial Agents; Female; Francisella tularensis; Germany; Humans; Levofloxacin; Male; Tick-Borne Diseases; Time Factors; Tularemia | 2015 |
Epidemiological and clinical characteristics and management of oropharyngeal tularemia outbreak.
Topics: Adolescent; Adult; Animals; Anti-Bacterial Agents; Disease Management; Disease Outbreaks; Disease Vectors; Doxycycline; Female; Francisella tularensis; Gentamicins; Humans; Lethargy; Levofloxacin; Lymphatic Diseases; Male; Middle Aged; Oropharynx; Streptomycin; Tularemia; Turkey | 2015 |
Nanoaerosols reduce required effective dose of liposomal levofloxacin against pulmonary murine Francisella tularensis subsp. novicida infection.
Topics: Aerosols; Animals; Anti-Bacterial Agents; Francisella tularensis; Levofloxacin; Liposomes; Lung; Mice; Mice, Inbred BALB C; Nanoparticles; Tularemia | 2016 |
A Bioluminescent Francisella tularensis SCHU S4 Strain Enables Noninvasive Tracking of Bacterial Dissemination and the Evaluation of Antibiotics in an Inhalational Mouse Model of Tularemia.
Topics: Animals; Anti-Bacterial Agents; Disease Models, Animal; Female; Francisella tularensis; Levofloxacin; Liver; Luminescent Measurements; Lymph Nodes; Mice; Mice, Inbred BALB C; Spleen; Tularemia | 2016 |
Levofloxacin rescues mice from lethal intra-nasal infections with virulent Francisella tularensis and induces immunity and production of protective antibody.
Topics: Administration, Intranasal; Animals; Anti-Bacterial Agents; Antibodies, Bacterial; Antibody Formation; Colony Count, Microbial; Enzyme-Linked Immunosorbent Assay; Female; Francisella tularensis; Levofloxacin; Mice; Mice, Inbred BALB C; Ofloxacin; Survival Analysis; Tularemia; Virulence; Zoonoses | 2008 |
Toll-like receptor 3 agonist protection against experimental Francisella tularensis respiratory tract infection.
Topics: Animals; Anti-Bacterial Agents; Bronchoalveolar Lavage Fluid; Cells, Cultured; Colony Count, Microbial; Cytokines; Female; Francisella tularensis; Humans; Immunologic Factors; Levofloxacin; Lung; Mice; Mice, Inbred BALB C; Monocytes; Neutrophils; Ofloxacin; Poly I-C; Respiratory Tract Infections; Survival Analysis; Toll-Like Receptor 3; Tularemia | 2010 |
[Localized inflammatory alopecia of the scalp: an unusual presentation of tularemia].
Topics: Alopecia; Anti-Bacterial Agents; Drug Resistance, Bacterial; Female; Humans; Levofloxacin; Lymphatic Diseases; Middle Aged; Ofloxacin; Scalp; Skin Diseases, Papulosquamous; Tularemia | 2012 |
Treatment of tularemia with levofloxacin.
Topics: Aged; Anti-Infective Agents; Francisella tularensis; Humans; Levofloxacin; Male; Ofloxacin; Tularemia | 2001 |